Aster DM Quality Care Ltd
Aster DM Quality Care Q2 Results 2026 (FY27) investor presentation: Revenue & Margins
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹2,829Cr
- Net profit
- ₹322Cr
- Margin
- 23.4%
Guidance rank: #3 of 32 in Healthcare Services
See the sector's top 10 — free with your mobile number.
Based on Aster DM Quality Care Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q2 FY27 revenue: INR 2,829 Cr, up 19% YoY from INR 2,382 Cr in Q2 FY26 (Page 6, 9, 10). Q2 FY27 Operating EBITDA: INR 678 Cr, up 25% YoY from INR 545 Cr (Page 17, 9).
From Aster DM Quality Care Ltd's Q2 FY27 earnings-call transcript · updated 6 Nov 2026.
How did Aster DM Quality Care's revenue grow in the September 2026 quarter?
- Q2 FY27 revenue: INR 2,829 Cr, up 19% YoY from INR 2,382 Cr in Q2 FY26 (Page 6, 9, 10).
- Q2 FY27 patient volumes: 2.18 million, up 12% YoY from 1.95 million in Q2 FY26 (Page 9).
- Operational beds increased 4% YoY to 10,611 in Q2 FY27 (Page 9).
- Revenue growth driven by 12% patient volume growth and 4% growth in operational beds (Page 9).
- CONGO specialty revenue grew 16-19% YoY, contributing 53-54% to overall revenue (Page 15, 26).
2 more points from Aster DM Quality Care Ltd's call on revenue
Create a free account to keep reading this call
What happened to Aster DM Quality Care's margins in Q2 FY27?
See what Aster DM Quality Care Ltd said on profitability & margins — free account, 30 seconds.
What capex is Aster DM Quality Care planning?
- Building a 15,000+ bed healthcare network; adding 4,230 beds to reach 15,070 total beds (Page 18).
- Planned bed additions by region (Page 27 & 28):
- Kerala & Tamil Nadu: 1,179 beds
- South-West & Central (Karnataka, Maharashtra, Madhya Pradesh, Chhattisgarh): 1,941 beds
- South-East (Andhra Pradesh, Telangana, Odisha, Bangladesh): 1,110 beds
- INR 1,200+ Cr capex invested including project capex, growth capex, and refresh over last 18 months (Page 11).
- Addition of medical technology assets in Q2 FY27: 1 LINAC, 1 Digital PET-CT, 3 robots, 2 cath labs, 1 MRI (Page 10).
- Commissioned a new 32-bed CARE Cancer Institute in Raipur, expanding advanced cancer care (Page 10).
- Planned bed capacity growth staged across FY27 to FY30 & beyond (Page 18):
- FY27: Addition of ~760 beds
- FY28: Addition of ~570 beds
2 more points from Aster DM Quality Care Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Aster DM Quality Care raising money or cutting debt?
See what Aster DM Quality Care Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Aster DM Quality Care's order book?
See what Aster DM Quality Care Ltd said on order book & pipeline — free account, 30 seconds.
Aster DM Quality Care Ltd — Quarterly revenue & net profit
Aster DM Quality Care Ltd Q2 FY27 results — key figures
| ₹ Cr | Q2 FY27 |
|---|---|
| Revenue | 2,829 |
| Operating profit (EBITDA) | 663 |
| Operating margin | 23.4% |
| Profit before tax | 427 |
| Net profit (PAT) | 322 |
| EPS (₹) | 3.19 |
Source: Aster DM Quality Care Ltd's results filing to NSE (consolidated), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹2.8K Cr, net profit ₹322 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Aster DM Quality's management said in earlier quarters
Others in Healthcare Services this season
- Nidan Laboratories & Healthcare (Q2 FY27)
Operating Margin: Not explicitly stated as a percentage; however, total income from operations is Rs 1,201.76 lakhs, so approximate operating margin = (EBITDA…
- Suven Life Sciences (Q2 FY27)
91.92 lakhs for the quarter ended September 30, 2025, indicating a revenue increase of approximately 30.3%. Key results statement takeaways from Suven Life Scie
- Fortis Healthcare (Q2 FY27)
Q2FY27 consolidated revenue: INR 2,735 Cr, up 17.3% YoY (Q2FY26: INR 2,331 Cr) [Pages 11, 33] . Key investor presentation takeaways from Fortis Healthcare Ltd's
- Dr Agarwal's Hea (Q2 FY27)
Q2 FY27 revenue from operations: ₹655 Cr, up 31.4% YoY from ₹499 Cr in Q2 FY26 (Page 24) . Key investor presentation takeaways from Dr Agarwals Health Care Ltd'
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- 3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Aster DM Quality Care Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Aster DM Quality Care Ltd Q2 FY27 results?
Q2 FY27 revenue: INR 2,829 Cr, up 19% YoY from INR 2,382 Cr in Q2 FY26 (Page 6, 9, 10). Q2 FY27 Operating EBITDA: INR 678 Cr, up 25% YoY from INR 545 Cr (Page 17, 9).
What is Aster DM Quality Care Ltd share price analysis?
Aster DM Quality Care Ltd currently shows a neutral. The stock trades at a P/E of 172.3 with a market cap of ₹62,196 Cr. Investors should review the full earnings analysis for detailed insights.
Is Aster DM Quality Care Ltd planning capital expenditure?
Building a 15,000+ bed healthcare network; adding 4,230 beds to reach 15,070 total beds (Page 18).
Keep Aster DM Quality Care Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
